Values fed to the model and their sources
| Clinical data | Values | Sources |
| First rehospitalisation rate due to graft of interest | 35.1% (177/504) | French rehospitalisation data, adjusted for mortality16 and contralateral reintervention15 |
| Added primary patency for Propaten grafts: | 75.6% | Own calculations (evidence acquisition) |
| Cost estimates | ||
| Mean initial intervention cost | €12 290 | Own calculations (PMSI based) |
| Rehospitalisation mean cost (one rehospitalisation) | €10 689 | Own calculations (PMSI based) |
| Propaten initial additional cost | €627 | WL Gore |
| PTFE reimbursement tariff | €639 | FNHI online data13 |
| Market data | ||
| Initial market penetration | 15% | De Cock17 |
| Annual market penetration increase | 5% | De Cock17 |
| Population growth | −1.0% | ATIH13 |
FNHI, French National Health Insurance; PMSI, French hospital expenditure database; PTFE, polytetrafluoroethylene.